Beyond sweetness: rare sugars as next-generation functional food ingredients for metabolic health, food innovation, and sugar-reduction strategies

Excessive consumption of added sugars has increased demand for food ingredients that reduce glycemic and caloric load while maintaining sweetness, bulk, processing functionality, and consumer acceptability. Rare sugars are low-abundance monosaccharides with compound-specific technological and physiological properties. This review critically synthesizes current evidence on their natural occurrence, structural chemistry, production, metabolic fate, food applications, safety, regulatory status, and translational potential. D-allulose and D-tagatose are among the most extensively studied rare sugars for food reformulation. Both provide sugar-like bulk and sensory functionality, lower energy contributions than sucrose, and evidence for attenuated postprandial glucose and insulin responses. Other rare monosaccharides, including D-allose, L-arabinose, L-xylulose, L-ribose, and D-sorbose, show distinct effects on digestion, microbial utilization, enzymatic recognition, and food-matrix behavior. Related polyols are chemically distinct and are considered only as relevant technological or physiological comparators. Rare sugars may influence browning, hydration, crystallization, fermentation, starch behavior, texture, and flavor development. Advances in enzymatic conversion, immobilized biocatalysis, microbial cell factories, synthetic biology, and waste-stream valorization have improved production feasibility. Nevertheless, conversion efficiency, purification requirements, production cost, and industrial scale-up remain important constraints. Human evidence is currently strongest for acute or short-term postprandial glycemic responses and gastrointestinal tolerability. In contrast, many findings concerning appetite regulation, cardiometabolic mechanisms, and gut-microbiota interactions remain dependent on animal, cellular, ex vivo , or mechanistic studies. These evidence categories should therefore not be interpreted as equivalent indicators of clinical efficacy. Overall, rare sugars represent promising ingredients for sugar reduction and functional-food development. Their successful translation requires compound-specific safety evaluation, realistic serving-size assessment, matrix-specific formulation studies, harmonized regulation, and longer-term controlled human studies.